The FDA move follows a determination that the disease constitutes a serious health challenge for patients from birth through age 18. VCA-894A, an antisense oligonucleotide therapy, targets the underlying mechanisms of the disorder, which typically manifests as severe muscle weakness and a gradual loss of motor function.
In section Market Quotes
Vanda Pharmaceuticals Secures FDA Rare Pediatric Designation for CMT2S
A rare inherited neurological disorder, Charcot-Marie-Tooth disease type 2S, has become the focus of a new regulatory push by Vanda Pharmaceuticals. The company announced Tuesday that its investigational therapy, VCA-894A, received the Rare Pediatric Disease Designation from the Food and Drug Administration to accelerate development for the progressive condition.
By securing this designation, Vanda gains a strategic foothold in the pediatric treatment landscape. If the therapy eventually receives full regulatory approval, the company may become eligible for a priority review voucher, a valuable asset that can be used to expedite the evaluation of future drug applications or sold to other developers.
Comments (0)
No comments yet. Be the first!